AF
RCKT icon

Amalgamated Financial’s Rocket Pharmaceuticals RCKT Stock Holding History

Amalgamated Financial’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$106K Buy
+6,711
New +$116K ﹤0.01% 2128

Other funds holding RCKT

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Amalgamated Financial's RCKT Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Rocket Pharmaceuticals (RCKT) in Q1 2022: 6,711 shares worth $106K. The stake represents ﹤0.01% of the portfolio and ranks #2128 among its holdings.

149 funds tracked by Wall St. Rank hold RCKT as of Q1 2022.

  • Amalgamated Financial held 6,711 shares of Rocket Pharmaceuticals worth $106K as of Q1 2022.
  • Rocket Pharmaceuticals was a new Amalgamated Financial position in Q1 2022.
  • Rocket Pharmaceuticals made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2128 holding.
  • 149 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.